Alabama senator joins push to restore safeguards on mail-order abortion drugs
Republican lawmakers say expanded access to mifepristone has left women vulnerable to medical risks and coercion and heightens dangers to the preborn.
U.S. Sen. Katie Britt, R-Ala., joined 90 Republican members of Congress in filing an amicus brief supporting Louisiana’s effort to reinstate the in-person dispensing requirement for the chemical abortion drug mifepristone.
According to a July 27 press release from Britt’s office, the brief, filed June 22 in the 5th U.S. Circuit Court of Appeals, supports Louisiana’s lawsuit challenging the Food and Drug Administration’s regulations allowing mifepristone to be prescribed online and sent by mail.
As Zeale News previously reported, chemical abortions now account for the majority of abortions nationwide following the Biden-era FDA’s elimination of the in-person dispensing requirement for mifepristone.
Britt said in the release that the growing availability of mail-order abortion drugs has endangered the preborn and left women more vulnerable to coercion.
“The rise of mail-order chemical abortion drugs endangers not only the lives of unborn babies,” she said, “but also the health and safety of their mothers. Not to mention the horrifying stories we have heard from women who have been subject to coercion and deception by abusers.”
The brief argues that the Biden administration’s removal of the in-person dispensing requirement violated federal law, relied on insufficient data to establish the safety of foregoing the requirement, and endangered women’s health.
The lawsuit at the center of the brief was filed in October 2025 by Louisiana Attorney General Liz Murrill on behalf of the state and state resident Rosalie Markezich, who alleges that her former boyfriend obtained abortion drugs by mail from a California doctor and coerced her into taking them in Louisiana in 2023, according to Alliance Defending Freedom, who is representing Markezich.
Britt said the filing is part of the lawmakers’ continued efforts to address their concerns about mifepristone.
“My colleagues and I,” she said, “will continue to fight every day to protect women and children from this dangerous drug by ensuring the rule of law is upheld.”
